Reports and Briefs on Pharmaceuticals and Healthcare in Europe

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
Report
Report

Myelodysplastic Syndrome: An Underserved Population Offers Commercial Opportunity

SuperGen/MGI Pharma's Dacogen and Celgene's Revlimid are in pre-registration for treatment of myelodysplastic syndrome (MDS). However, a significant proportion of the MDS population will be left underserved by pharmacotherapy.

Published By Datamonitor
18 Oct 2005 $1900
Buy
Report
Report

Commercial Insight: Osteoporosis - Market players maximize revenue growth before the next challenging phase

Comprehensive analysis of the current and future osteoporosis drug market, with country-specific forecasts to 2019 of marketed, generic, and key pipeline drugs in the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK).

Published By Datamonitor
21 Jul 2010 $15200
Buy
Report
Report

Pipeline Insight: Osteoporosis - Bone building drugs become the heart of the pipeline

In-depth analysis of the osteoporosis drug pipeline, including a review of clinical unmet needs, assessment of the clinical and commercial prospects of 12 key late-stage agents, sales forecasts to 2019 and key opinion leader insight.

Published By Datamonitor
21 Jul 2010 $11400
Buy
Report
Report

Commercial Insight: Inflammatory Bowel Disease - Future market prospects rely on addressing cost and safety

Coverage of the inflammatory bowel disease (IBD) market, including indication-specific 10-year forecasts, detailed brand profiling, opportunities and threats, and a scenario-based case study.

Published By Datamonitor
05 Aug 2010 $15200
Buy
Report
Report

Stakeholder Opinions: Sexually Transmitted Diseases - An underestimated threat lacking interventions to prevent transmission

This report covers 4 STDs: chlamydia, gonorrhea, human papillomavirus (HPV), and herpes simplex virus type 2 (HSV-2). It discusses disease background, epidemiology, unmet needs as well as marketed and pipeline therapeutic and preventative strategies.

Published By Datamonitor
05 Aug 2010 $3800
Buy
Report
Report

Pipeline and Commercial Insight: Moderate to Severe Chronic Nociceptive Pain - Anti-abuse opioids set to prosper

Analysis of the current and future moderate to severe chronic nociceptive pain market with sales forecasts to 2019 across the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK) of key brands, generics, and pipeline products.

Published By Datamonitor
20 Aug 2010 $15200
Buy
Report
Report

Stakeholder Insight: Gastric Cancer

Explores key issues in the gastric cancer market, including diagnosis and treatment patterns, specific drug regimens used at each line of therapy, key prescribing influences and predicted performance of late-phase pipeline products.

Published By Datamonitor
15 Sep 2010 $15200
Buy
Report
Report

Stakeholder Insight: Rheumatoid arthritis - Rising competition by line and severity

Datamonitor surveyed 183 rheumatologists in the seven major markets to gain insight into rheumatoid arthritis diagnosis, patient segmentation, current and future prescribing patterns, factors influencing decision making and key treatment challenges.

Published By Datamonitor
17 Sep 2010 $15200
Buy
Report
Report

Pipeline and Commercial Insight: Hormonal Replacement Therapy for Menopausal Symptoms - Safety fears continue to haunt the market

In-depth analysis of the current and future hormonal replacement therapy (HRT) for menopausal symptoms market across the seven major countries (US, Japan, France, Germany, Italy, Spain, UK), supported by key opinion leader comment.

Published By Datamonitor
27 Sep 2010 $15200
Buy
Report
Report

Pipeline and Commercial Insight: Testosterone Replacement Therapy - Topical formulations drive market growth

In-depth analysis of the current and future testosterone replacement therapy prescription market across the seven major markets (US, Japan, France, Germany, Italy, Spain, UK), supported by key opinion leader insight.

Published By Datamonitor
27 Sep 2010 $15200
Buy

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.